|
Delayed
Sao Paulo
12:56:10 06/10/26 am AEDT
|
5-day change | 1st Jan Change | ||
| 60.71 BRL | -4.81% |
|
-8.02% | -14.38% |
| 02/10 | Jefferies Raises Regeneron Pharmaceuticals Price Target to $930 From $870, Maintains Buy Rating | MT |
| 02/10 | Major drugmakers turn to China for licensing deals | RE |
| Market Cap | 73.41B 384B 65.23B 60.88B 55.49B 105B 7,057B 106B 737B 285B 3,608B 276B 270B 11,579B | P/E 2026 * |
16.8x | P/E 2027 * | 14.5x |
|---|---|---|---|---|---|
| Enterprise Value | 65.99B 345B 58.63B 54.72B 49.88B 94.07B 6,344B 94.95B 662B 257B 3,243B 248B 242B 10,408B | EV / Sales 2026 * |
3.88x | EV / Sales 2027 * | 3.41x |
| Free-Float |
71.06% | Yield 2026 * |
0.53% | Yield 2027 * | 0.6% |
Last Transcript: Regeneron Pharmaceuticals, Inc.
| 1 day | -4.81% | ||
| 1 week | -8.02% | ||
| Current month | -7.24% | ||
| 1 month | -13.78% | ||
| 3 months | +9.05% | ||
| 6 months | -7.09% | ||
| Current year | -14.38% |
| 1 week | 60.71 |  | 65.45 |
| 1 month | 60.71 | | 70.6 |
| Current year | 50 | | 73.16 |
| 1 year | 49.65 | | 73.33 |
| 3 years | 44.82 | | 111.72 |
| 5 years | 44.82 | | 111.72 |
| 10 years | 18.16 | | 111.72 |
| Manager | Title | Age | Since |
|---|---|---|---|
| President | 66 | 01/01/2001 | |
| Chief Executive Officer | 73 | 08/01/1988 | |
| Director of Finance/CFO | 55 | 05/02/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 73 | 09/06/2023 | |
Joseph Goldstein
BRD | Director/Board Member | 85 | 01/06/1991 |
George Sing
BRD | Director/Board Member | 76 | 08/01/1988 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.81% | -8.02% | - | - | 73.41B | |
| +0.87% | -2.39% | +36.86% | +113.58% | 1,019B | |
| -0.91% | -6.32% | +35.40% | +62.12% | 617B | |
| -0.36% | -1.54% | +13.90% | +77.81% | 464B | |
| -3.34% | -5.54% | +58.16% | +35.57% | 356B | |
| +0.33% | -2.42% | +20.25% | +40.58% | 333B | |
| -0.07% | -4.05% | +10.09% | +33.53% | 267B | |
| -1.01% | -5.76% | -7.50% | +7.98% | 244B | |
| -0.79% | -4.09% | +36.34% | +51.28% | 218B | |
| -0.95% | -5.38% | +26.80% | +92.80% | 179B | |
| Average | -1.07% | -3.54% | +25.59% | +57.25% | 410.8B | |
| Weighted average by Cap. | -0.49% | -3.54% | +28.91% | +68.99% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 17.01B 89.06B 15.12B 14.11B 12.86B 24.25B 1,636B 24.48B 171B 66.16B 836B 63.88B 62.49B 2,683B | 18.51B 96.9B 16.45B 15.35B 13.99B 26.39B 1,780B 26.63B 186B 71.99B 910B 69.5B 67.99B 2,920B |
| Net income | 4.95B 25.92B 4.4B 4.11B 3.74B 7.06B 476B 7.12B 49.69B 19.26B 243B 18.59B 18.19B 781B | 5.49B 28.72B 4.87B 4.55B 4.15B 7.82B 527B 7.89B 55.05B 21.33B 270B 20.6B 20.15B 865B |
| Net Debt | -7.42B -38.85B -6.59B -6.15B -5.61B -10.58B -714B -10.68B -74.48B -28.86B -365B -27.87B -27.26B -1,171B | -10.32B -54B -9.17B -8.55B -7.8B -14.71B -992B -14.84B -104B -40.12B -507B -38.73B -37.89B -1,627B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 06/10/26 | BRL 60.71 | -4.81% | 123 |
| 02/10/26 | BRL 63.78 | -1.39% | 6,817 |
| 01/10/26 | BRL 64.68 | -1.18% | 58 |
| 30/09/26 | BRL 65.45 | +0.43% | 127 |
| 29/09/26 | BRL 65.17 | -1.26% | 348 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- REGN Stock
- REGN34 Stock
Select your edition
All financial news and data tailored to specific country editions
